Sana Biotechnology, Inc. (SANA)Healthcare | Biotechnology | Seattle, United States | NasdaqGS
3.64 USD
-0.21
(-5.455%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.69 +0.05 (1.374%) ⇧ (July 13, 2026, 7:42 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:12 a.m. EDT
The investment case for Sana Biotechnology is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. The stock has lost over 77% of its value over the last four years, with every single year showing negative returns, including a brutal 56% drop in the first year of the window. This is not a temporary setback; it is a structural implosion where the market has repeatedly rejected the business thesis. Fundamentally, the company is bleeding cash with negative free cash flow and negative returns on equity, while trading at a premium to book value despite having no earnings. The recent news of insider sales and class-action lawsuits further erodes trust in management's stewardship. While the analyst consensus remains optimistic with a high price target, this appears to be a disconnect between Wall Street models and the harsh reality of the share price action. Options data confirms this pessimism, with traders heavily stacking protection at lower strikes. There is no catalyst visible to reverse this trend, making this a dangerous speculative vehicle rather than an investment opportunity. |
| Model | MAE |
|---|---|
| MSTL_90 ✓ | 0.079422 |
| AutoTheta | 0.085795 |
| MSTL_74_90 | 0.087662 |
| AutoETS | 0.091964 |
| AutoARIMA | 0.091964 |
| MSTL | 0.092221 |
| MSTL_74 | 0.116060 |
Forecast horizon: 60 days | Selected: MSTL_90
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.816 |
| Excess Kurtosis | -0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 69.296 |
| Market Cap | 1,012,981,376 |
| Forward P/E | -6.97 |
| Beta | 2.14 |
| Website | https://www.sana.com |
As of July 11, 2026, 3:12 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly at the $2.50 strike where open interest is significantly higher than call counterparties. While there is some call activity at the $7.50 strike, the overwhelming majority of open interest sits out-of-the-money on the put side, suggesting a strong expectation of further downside or a 'crash' scenario rather than a rally. Implied volatility is elevated on near-term puts compared to calls, indicating fear of a sharp drop.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08767772 |
| Address1 | 188 East Blaine Street |
| Address2 | Suite 400 |
| All Time High | 44.6 |
| All Time Low | 1.26 |
| Ask | 3.66 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 3,918,230 |
| Average Daily Volume3 Month | 4,052,340 |
| Average Volume | 4,052,340 |
| Average Volume10Days | 3,918,230 |
| Beta | 2.143 |
| Bid | 2.72 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.442 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.64 |
| Current Ratio | 1.295 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.78 |
| Day Low | 3.56 |
| Debt To Equity | 69.296 |
| Display Name | Sana Biotechnology |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -168,568,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.9 |
| Enterprise Value | 994,473,408 |
| Eps Current Year | -0.5795 |
| Eps Forward | -0.52226 |
| Eps Trailing Twelve Months | -0.92 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.269 |
| Fifty Day Average Change | 0.37100005 |
| Fifty Day Average Change Percent | 0.11349038 |
| Fifty Two Week Change Percent | -8.767772 |
| Fifty Two Week High | 6.55 |
| Fifty Two Week High Change | -2.91 |
| Fifty Two Week High Change Percent | -0.4442748 |
| Fifty Two Week Low | 2.61 |
| Fifty Two Week Low Change | 1.0300002 |
| Fifty Two Week Low Change Percent | 0.39463612 |
| Fifty Two Week Range | 2.61 - 6.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,449,000,000 |
| Float Shares | 177,717,009 |
| Forward Eps | -0.52226 |
| Forward P E | -6.9697084 |
| Free Cashflow | -29,722,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 142 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0651 |
| Held Percent Institutions | 0.82834 |
| Implied Shares Outstanding | 278,291,590 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. |
| Long Name | Sana Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 1,012,981,376 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_597313585 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -241,987,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,071,422,621 |
| Number Of Analyst Opinions | 7 |
| Open | 3.77 |
| Operating Cashflow | -132,550,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 206 701 7914 |
| Post Market Change | 0.049999952 |
| Post Market Change Percent | 1.373625 |
| Post Market Price | 3.69 |
| Post Market Time | 1,783,986,167 |
| Previous Close | 3.85 |
| Price Eps Current Year | -6.2812767 |
| Price Hint | 4 |
| Price To Book | 8.235294 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.172 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.21 |
| Regular Market Change Percent | -5.45454 |
| Regular Market Day High | 3.78 |
| Regular Market Day Low | 3.56 |
| Regular Market Day Range | 3.56 - 3.78 |
| Regular Market Open | 3.77 |
| Regular Market Previous Close | 3.85 |
| Regular Market Price | 3.64 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,465,302 |
| Return On Assets | -0.2748 |
| Return On Equity | -1.4741 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 278,291,590 |
| Shares Percent Shares Out | 0.1391 |
| Shares Short | 38,698,572 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 39,329,730 |
| Short Name | Sana Biotechnology, Inc. |
| Short Percent Of Float | 0.2476 |
| Short Ratio | 9.72 |
| Source Interval | 15 |
| State | WA |
| Symbol | SANA |
| Target High Price | 12.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 8.57143 |
| Target Median Price | 7.0 |
| Total Cash | 101,136,000 |
| Total Cash Per Share | 0.363 |
| Total Debt | 82,628,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.92 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.8725 |
| Two Hundred Day Average Change | -0.23249984 |
| Two Hundred Day Average Change Percent | -0.060038693 |
| Type Disp | Equity |
| Volume | 2,465,302 |
| Website | https://www.sana.com |
| Zip | 98,102 |